Copyright Reports & Markets. All rights reserved.

Global Personalized Medicine and Epigenomics Market Size, Status and Forecast 2019-2025

Request for Sample of this report
Buy now

Table of Contents

    1 Report Overview

    • 1.1 Study Scope
    • 1.2 Key Market Segments
    • 1.3 Players Covered
    • 1.4 Market Analysis by Type
      • 1.4.1 Global Personalized Medicine and Epigenomics Market Size Growth Rate by Type (2014-2025)
      • 1.4.2 Reagents
      • 1.4.3 Kits
      • 1.4.4 Instruments
      • 1.4.5 Enzymes
      • 1.4.6 Services
    • 1.5 Market by Application
      • 1.5.1 Global Personalized Medicine and Epigenomics Market Share by Application (2014-2025)
      • 1.5.2 Oncology
      • 1.5.3 Non-Oncology
      • 1.5.4 Cancer Drug Technology
    • 1.6 Study Objectives
    • 1.7 Years Considered

    2 Global Growth Trends

    • 2.1 Personalized Medicine and Epigenomics Market Size
    • 2.2 Personalized Medicine and Epigenomics Growth Trends by Regions
      • 2.2.1 Personalized Medicine and Epigenomics Market Size by Regions (2014-2025)
      • 2.2.2 Personalized Medicine and Epigenomics Market Share by Regions (2014-2019)
    • 2.3 Industry Trends
      • 2.3.1 Market Top Trends
      • 2.3.2 Market Drivers
      • 2.3.3 Market Opportunities

    3 Market Share by Key Players

    • 3.1 Personalized Medicine and Epigenomics Market Size by Manufacturers
      • 3.1.1 Global Personalized Medicine and Epigenomics Revenue by Manufacturers (2014-2019)
      • 3.1.2 Global Personalized Medicine and Epigenomics Revenue Market Share by Manufacturers (2014-2019)
      • 3.1.3 Global Personalized Medicine and Epigenomics Market Concentration Ratio (CR5 and HHI)
    • 3.2 Personalized Medicine and Epigenomics Key Players Head office and Area Served
    • 3.3 Key Players Personalized Medicine and Epigenomics Product/Solution/Service
    • 3.4 Date of Enter into Personalized Medicine and Epigenomics Market
    • 3.5 Mergers & Acquisitions, Expansion Plans

    4 Breakdown Data by Type and Application

    • 4.1 Global Personalized Medicine and Epigenomics Market Size by Type (2014-2019)
    • 4.2 Global Personalized Medicine and Epigenomics Market Size by Application (2014-2019)

    5 United States

    • 5.1 United States Personalized Medicine and Epigenomics Market Size (2014-2019)
    • 5.2 Personalized Medicine and Epigenomics Key Players in United States
    • 5.3 United States Personalized Medicine and Epigenomics Market Size by Type
    • 5.4 United States Personalized Medicine and Epigenomics Market Size by Application

    6 Europe

    • 6.1 Europe Personalized Medicine and Epigenomics Market Size (2014-2019)
    • 6.2 Personalized Medicine and Epigenomics Key Players in Europe
    • 6.3 Europe Personalized Medicine and Epigenomics Market Size by Type
    • 6.4 Europe Personalized Medicine and Epigenomics Market Size by Application

    7 China

    • 7.1 China Personalized Medicine and Epigenomics Market Size (2014-2019)
    • 7.2 Personalized Medicine and Epigenomics Key Players in China
    • 7.3 China Personalized Medicine and Epigenomics Market Size by Type
    • 7.4 China Personalized Medicine and Epigenomics Market Size by Application

    8 Japan

    • 8.1 Japan Personalized Medicine and Epigenomics Market Size (2014-2019)
    • 8.2 Personalized Medicine and Epigenomics Key Players in Japan
    • 8.3 Japan Personalized Medicine and Epigenomics Market Size by Type
    • 8.4 Japan Personalized Medicine and Epigenomics Market Size by Application

    9 Southeast Asia

    • 9.1 Southeast Asia Personalized Medicine and Epigenomics Market Size (2014-2019)
    • 9.2 Personalized Medicine and Epigenomics Key Players in Southeast Asia
    • 9.3 Southeast Asia Personalized Medicine and Epigenomics Market Size by Type
    • 9.4 Southeast Asia Personalized Medicine and Epigenomics Market Size by Application

    10 India

    • 10.1 India Personalized Medicine and Epigenomics Market Size (2014-2019)
    • 10.2 Personalized Medicine and Epigenomics Key Players in India
    • 10.3 India Personalized Medicine and Epigenomics Market Size by Type
    • 10.4 India Personalized Medicine and Epigenomics Market Size by Application

    11 Central & South America

    • 11.1 Central & South America Personalized Medicine and Epigenomics Market Size (2014-2019)
    • 11.2 Personalized Medicine and Epigenomics Key Players in Central & South America
    • 11.3 Central & South America Personalized Medicine and Epigenomics Market Size by Type
    • 11.4 Central & South America Personalized Medicine and Epigenomics Market Size by Application

    12 International Players Profiles

    • 12.1 Abbott Laboratories
      • 12.1.1 Abbott Laboratories Company Details
      • 12.1.2 Company Description and Business Overview
      • 12.1.3 Personalized Medicine and Epigenomics Introduction
      • 12.1.4 Abbott Laboratories Revenue in Personalized Medicine and Epigenomics Business (2014-2019)
      • 12.1.5 Abbott Laboratories Recent Development
    • 12.2 Affymetrix
      • 12.2.1 Affymetrix Company Details
      • 12.2.2 Company Description and Business Overview
      • 12.2.3 Personalized Medicine and Epigenomics Introduction
      • 12.2.4 Affymetrix Revenue in Personalized Medicine and Epigenomics Business (2014-2019)
      • 12.2.5 Affymetrix Recent Development
    • 12.3 Agilent Technologies
      • 12.3.1 Agilent Technologies Company Details
      • 12.3.2 Company Description and Business Overview
      • 12.3.3 Personalized Medicine and Epigenomics Introduction
      • 12.3.4 Agilent Technologies Revenue in Personalized Medicine and Epigenomics Business (2014-2019)
      • 12.3.5 Agilent Technologies Recent Development
    • 12.4 Astellas Pharmaceuticals
      • 12.4.1 Astellas Pharmaceuticals Company Details
      • 12.4.2 Company Description and Business Overview
      • 12.4.3 Personalized Medicine and Epigenomics Introduction
      • 12.4.4 Astellas Pharmaceuticals Revenue in Personalized Medicine and Epigenomics Business (2014-2019)
      • 12.4.5 Astellas Pharmaceuticals Recent Development
    • 12.5 BAYER AG
      • 12.5.1 BAYER AG Company Details
      • 12.5.2 Company Description and Business Overview
      • 12.5.3 Personalized Medicine and Epigenomics Introduction
      • 12.5.4 BAYER AG Revenue in Personalized Medicine and Epigenomics Business (2014-2019)
      • 12.5.5 BAYER AG Recent Development
    • 12.6 Bio Vision
      • 12.6.1 Bio Vision Company Details
      • 12.6.2 Company Description and Business Overview
      • 12.6.3 Personalized Medicine and Epigenomics Introduction
      • 12.6.4 Bio Vision Revenue in Personalized Medicine and Epigenomics Business (2014-2019)
      • 12.6.5 Bio Vision Recent Development
    • 12.7 Celgene Corp.
      • 12.7.1 Celgene Corp. Company Details
      • 12.7.2 Company Description and Business Overview
      • 12.7.3 Personalized Medicine and Epigenomics Introduction
      • 12.7.4 Celgene Corp. Revenue in Personalized Medicine and Epigenomics Business (2014-2019)
      • 12.7.5 Celgene Corp. Recent Development
    • 12.8 Emd Millipore
      • 12.8.1 Emd Millipore Company Details
      • 12.8.2 Company Description and Business Overview
      • 12.8.3 Personalized Medicine and Epigenomics Introduction
      • 12.8.4 Emd Millipore Revenue in Personalized Medicine and Epigenomics Business (2014-2019)
      • 12.8.5 Emd Millipore Recent Development
    • 12.9 Epigenomics AG
      • 12.9.1 Epigenomics AG Company Details
      • 12.9.2 Company Description and Business Overview
      • 12.9.3 Personalized Medicine and Epigenomics Introduction
      • 12.9.4 Epigenomics AG Revenue in Personalized Medicine and Epigenomics Business (2014-2019)
      • 12.9.5 Epigenomics AG Recent Development
    • 12.10 Epigentex
      • 12.10.1 Epigentex Company Details
      • 12.10.2 Company Description and Business Overview
      • 12.10.3 Personalized Medicine and Epigenomics Introduction
      • 12.10.4 Epigentex Revenue in Personalized Medicine and Epigenomics Business (2014-2019)
      • 12.10.5 Epigentex Recent Development
    • 12.11 Envivo Pharmaceuticals (Forum Pharmaceutricals)
    • 12.12 Gilead Sciences
    • 12.13 Glaxosmithkline
    • 12.14 Illumina Inc.
    • 12.15 Johnson & Johnson
    • 12.16 Karus Therapeutics Limited
    • 12.17 Laboratory Corp. Of America Holdings
    • 12.18 LES Laboratoires Servier
    • 12.19 Merck
    • 12.20 Naturewise Biotech & Medicals Corp.
    • 12.21 Novartis Pharma AG
    • 12.22 Oncolys Biopharma Inc.
    • 12.23 Orchid Chemicals & Pharmaceuticals Limited
    • 12.24 Progen Pharmaceuticals Limited
    • 12.25 Quest Diagnostics
    • 12.26 Roche Holding AG
    • 12.27 Rubicon Genomics
    • 12.28 Takeda Pharmaceutical Company Limited

    13 Market Forecast 2019-2025

    • 13.1 Market Size Forecast by Regions
    • 13.2 United States
    • 13.3 Europe
    • 13.4 China
    • 13.5 Japan
    • 13.6 Southeast Asia
    • 13.7 India
    • 13.8 Central & South America
    • 13.9 Market Size Forecast by Product (2019-2025)
    • 13.10 Market Size Forecast by Application (2019-2025)

    14 Analyst's Viewpoints/Conclusions

      15 Appendix

      • 15.1 Research Methodology
        • 15.1.1 Methodology/Research Approach
          • 15.1.1.1 Research Programs/Design
          • 15.1.1.2 Market Size Estimation
          • 12.1.1.3 Market Breakdown and Data Triangulation
        • 15.1.2 Data Source
          • 15.1.2.1 Secondary Sources
          • 15.1.2.2 Primary Sources
      • 15.2 Disclaimer

      Epigenomics is the study of the complete set of epigenetic modifications on the genetic material of a cell, known as the epigenome. The field is analogous to genomics and proteomics, which are the study of the genome and proteome of a cell.
      In 2018, the global Personalized Medicine and Epigenomics market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2019-2025.

      This report focuses on the global Personalized Medicine and Epigenomics status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Personalized Medicine and Epigenomics development in United States, Europe and China.

      The key players covered in this study
      Abbott Laboratories
      Affymetrix
      Agilent Technologies
      Astellas Pharmaceuticals
      BAYER AG
      Bio Vision
      Celgene Corp.
      Emd Millipore
      Epigenomics AG
      Epigentex
      Envivo Pharmaceuticals (Forum Pharmaceutricals)
      Gilead Sciences
      Glaxosmithkline
      Illumina Inc.
      Johnson & Johnson
      Karus Therapeutics Limited
      Laboratory Corp. Of America Holdings
      LES Laboratoires Servier
      Merck
      Naturewise Biotech & Medicals Corp.
      Novartis Pharma AG
      Oncolys Biopharma Inc.
      Orchid Chemicals & Pharmaceuticals Limited
      Progen Pharmaceuticals Limited
      Quest Diagnostics
      Roche Holding AG
      Rubicon Genomics
      Takeda Pharmaceutical Company Limited

      Market segment by Type, the product can be split into
      Reagents
      Kits
      Instruments
      Enzymes
      Services

      Market segment by Application, split into
      Oncology
      Non-Oncology
      Cancer Drug Technology

      Market segment by Regions/Countries, this report covers
      United States
      Europe
      China
      Japan
      Southeast Asia
      India
      Central & South America

      The study objectives of this report are:
      To analyze global Personalized Medicine and Epigenomics status, future forecast, growth opportunity, key market and key players.
      To present the Personalized Medicine and Epigenomics development in United States, Europe and China.
      To strategically profile the key players and comprehensively analyze their development plan and strategies.
      To define, describe and forecast the market by product type, market and key regions.

      In this study, the years considered to estimate the market size of Personalized Medicine and Epigenomics are as follows:
      History Year: 2014-2018
      Base Year: 2018
      Estimated Year: 2019
      Forecast Year 2019 to 2025
      For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

      Buy now